Pancreatic Neuroendocrine Tumors: Analysis of Prognostic Factors After Surgical Resection in a Single Centre Abstract #2204

Introduction: Pancreatic neuroendocrine tumors (PNET) are rare, heterogeneous and challenging neoplasms. Surgical resection is the only curative treatment. Recurrence can occur even after years. Diagnosis of malignancy is difficult so further studies are necessary to identify prognostic criteria.
Aim(s): To evaluate prognostic factors related with disease recurrence and mortality in patients with PNET resected in our institution.
Materials and methods: Retrospective study of patients with PNET who underwent surgery in our hospital between January 2000 and July 2017. We analyse clinical, surgical (technique, complications) and pathological (size, stage, grade, Ki67, lymph node, metastasis) parameters to identify recurrence risk factors.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: MD Laia Blanco Cuso
Keywords: PNETS, Prognosis

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1076 “Wait and Watch” Approach for Small Pancreatic Neuroendocrine Tumors (pNETs): Prognosis and Survival in 51 Consecutive Patients.
Introduction: The most appropriate management for small non-functioning pancreatic neuroendocrine tumors (pNETs) is lacking and whether all these lesions should be routinely resected is still debatable
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: MD Roberta Elisa Rossi
#1854 VHL Genotype Is Associated with Pancreatic Neuroendocrine Tumors (PNETs) Phenotype in Patients with Von Hippel-Lindau Disease (VHLD)
Introduction: 8-20% of patients with VHLD develop PNETs. However, there are no markers for PNETs progression in VHLD patients. The type of mutation in VHL gene is associated with clinical phenotype of VHLD.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: MD Amit Tirosh
Keywords: VHL, mutation, prognosis
#2114 Significance of Biochemical Testing in Pancreatic Neuroendocrine Tumors
Introduction: Pancreatic neuroendocrine tumors (PNETs) are rare tumors that are frequently diagnosed late in the course of the disease. Several biomarkers have been proposed in the literature for diagnosis in patients with these tumors.
Conference: 15th Annual ENETS conference (2018)
Category: Biomarkers
Presenting Author: Doctor Azka Athar
Authors: Athar A, , , , ...
#1430 Cystic Neuroendocrine Tumors of the Pancreas (c-pNETs): A Single-Center Experience.
Introduction: c-pNETs are rare and may be less aggressive than their solid counterparts
Conference: 13th Annual ENETS conference (2016)
Category: Clinical cases/reports
Presenting Author: Dr. Thorvardur Halfdanarson
#1907 Pancreatic Neuroendocrine Tumors in MEN1 Disease: A Monocentrice Longitudinal and Prognostic Study
Introduction: In MEN1+ patients (MEN+), pNETs are considered to be high risk for multiple, malignant and aggressive tumors.
Conference: 14th Annual ENETS conference (2017)
Category: Pathology, grading, staging
Presenting Author: md Sabrina Chiloiro
Keywords: pNETs, MEN, prognosis